Proton Pump Inhibitor Prescription in Patients with Liver Cirrhosis: Indications in Theory and the Real World

Picardi, Antonio

doi:10.15406/jlrdt.2015.01.00003

Cited by 2 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is unclear whether this might contribute to bleeding from varices [8]. Data on management of GERD in cirrhosis are few, however, the indications of use for PPIs may remain exactly the same in patient with cirrhosis of the liver as general population for the treatment of erosive esophagitis, or in general the pathology secondary to gastroesophageal reflux of acid [10].…”

Section: Gerdmentioning

confidence: 99%

Insights to Indications and Harm of Proton Pump Inhibitors Usage in Patients with Liver Cirrhosis

Wadea¹

2017

GHOA

View full text Add to dashboard Cite

show abstract

Section: Gerdmentioning

confidence: 99%

Insights to Indications and Harm of Proton Pump Inhibitors Usage in Patients with Liver Cirrhosis

Wadea¹

2017

GHOA

View full text Add to dashboard Cite

show abstract

“…In this case, the treatment of gastrointestinal bleeding could be ineffective. It has been reported that the prevalence of peptic pathology in cirrhotic patients is not more than 20%; however, over 60% of patients with liver cirrhosis are prescribed proton pump inhibitors [25]. In cirrhotic patients who present with acute upper gastrointestinal bleeding, variceal hemorrhage must be suspected and treatment initiated with vasoactive drugs (e.g., somatosatin, terlipressin, or octreotide) and antibiotic prophylaxis [7,26].…”

mentioning

confidence: 99%

Drug Treatment of Patients with Liver Cirrhosis in a Tertiary Hospital in Northern Ghana: Does It Comply with Recommended Guidelines?

Mohammed

Aidoo

2020

International Journal of Hepatology

View full text Add to dashboard Cite

The diverse influence of liver function on drug disposition can lead health-care practitioners to inappropriate drug selection, inappropriate drug dosing, or some level of therapeutic negativism. The aim of this study was to assess how drug prescribing in patients with liver cirrhosis at the Tamale Teaching Hospital comply with recommendations of pharmacotherapy and safety guidelines. A prospective cross-sectional study was conducted from February to July, 2019, at the medical ward of the Tamale Teaching Hospital. A total of 152 liver cirrhotic patients were included in this study. Common etiologies for liver cirrhosis were chronic hepatitis B 80 (52.6%) and chronic hepatitis C 30 (19.7%); about 12.5% of etiologies were unknown. Of the 1842 prescription issued, 69% (1270/1842) were compliant. Of the 572 noncompliant prescriptions, about 32% (183/572) were due to pharmacotherapy and 68% (389/572) due to safety guideline recommendations. There was a substantial number (31%) of prescription noncompliance with recommendations for pharmacotherapy and safety guidelines in liver cirrhotic patients at the tertiary hospital in northern Ghana. Prescribers need to be conscious of the role of the liver in drug elimination and prescribe as recommended by guidelines.

show abstract

Proton Pump Inhibitor Prescription in Patients with Liver Cirrhosis: Indications in Theory and the Real World

Cited by 2 publications

References 34 publications

Insights to Indications and Harm of Proton Pump Inhibitors Usage in Patients with Liver Cirrhosis

Insights to Indications and Harm of Proton Pump Inhibitors Usage in Patients with Liver Cirrhosis

Drug Treatment of Patients with Liver Cirrhosis in a Tertiary Hospital in Northern Ghana: Does It Comply with Recommended Guidelines?

Contact Info

Product

Resources

About